DRRX
vs
S&P 500
DRRX
S&P 500
Over the past 12 months, DRRX has significantly outperformed S&P 500, delivering a return of +142% compared to the S&P 500's +13% growth.
Stocks Performance
DRRX vs S&P 500
Performance Gap
DRRX vs S&P 500
Performance By Year
DRRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
DURECT Corp
Glance View
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 79 full-time employees. The company went IPO on 2000-09-28. The firm's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The firm is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with severe alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The firm focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug.
